Search

IR502

IR502 (Zorcell) is a potential treatment for psoriasis.

Briakinumab

As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe. … Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases.

Vibriolysin

Vibriolysin is a proteolytic enzyme secreted by the marine microorganism Vibrio proteolyticus. … It is a new agent for enzymatic debridement, shown to rapidly and thoroughly hydrolyze burn wound eschar within full-thickness wounds.

BIIB015

BIIB015 is a humanized, IgG1 [immunoglobulin G 1], DM4-Conjugated, anti-cripto, monoclonal antibody. It has been investigated for the treatment of subjects with relapsed or refractory solid tumours.

Homatropine methylbromide

Homatropine methylbromide is a quaternary ammonium muscarinic acetylcholine receptor antagonist belonging to the group of medicines called anti-muscarinics. … Homatropine is used to treat duodenal or stomach ulcers or intestine problems. It can be used together with antacids or other medicine in the treatment of peptic ulcer.

Abafungin

Porfimer sodium

It is the first drug to be approved in the use of photodynamic therapy in the United States. … It is used in photodynamic therapy (hematoporphyrin photoradiation); to treat malignant lesions with visible light and experimentally as an antiviral agent.

IP501

IP-501 is an investigational antifibrotic compound being tested for the treatment of alcohol-induced liver disease and chronic hepatitis-C-induced cirrhosis.

XP12B

XP12B is being developed by Xanodyne Pharmaceuticals for the treatment of menorrhagia (heavy menstrual bleeding). It was granted Fast Track status for this indication by the FDA in November 2004.

Exemestane

Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal